CANTON, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that second quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, August 7th. Management will host a conference call at 5:00 p.m. Eastern Time on August 7th to dis ...

Adia Nutrition Partners with CareCredit to Offer up to $25,000 in Affordable Financing for Patient TreatmentsJuly 16, 2025 9:01 AM EDT | Source: Adia Nutrition Inc.Winter Park, Florida--(Newsfile Corp. - July 16, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), an emerging leader in regenerative medicine and personalized wellness solutions, is excited to announce its approval to offer CareCredit's payment plan program to patients, tapping into the $48.35 billion U.S. healthcare finance solutions mar ...

Forward-Looking Statements This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward- looking statements may be identified by the use of words such as "will," "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or ...

Adia Nutrition Inc. Celebrates Grand Opening of Adia Med of San Antonio, First Licensed Clinic, Led by Michele DeLeon MDJuly 14, 2025 9:28 AM EDT | Source: Adia Nutrition Inc.Winter Park, Florida--(Newsfile Corp. - July 14, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), an emerging leader in regenerative medicine, proudly announces the grand opening of Adia Med of San Antonio, its first licensed clinic under a strategic license agreement, located at 18707 Hardy Oak Blvd, Suite 500, San Antonio, Te ...

Core Insights - Creative Medical Technology Holdings, Inc. has received a Notice of Allowance for a U.S. patent related to treating heart failure and post-infarct pathological remodeling using its ImmCelz product, with the patent expected to be effective until at least 2040 [1][2]. Group 1: Patent and Product Details - The patent covers treatment for patients at risk of or already experiencing heart failure, utilizing the proprietary ImmCelz product [2]. - The total addressable market for heart failure treatment in the U.S. exceeds five million patients, with an additional six million patients suffering from chronic chest pain who may benefit from the ImmCelz product [2]. - ImmCelz is administered through an ultra-minimally invasive outpatient procedure [2]. Group 2: Company Strategy and Technology - The CEO of Creative Medical emphasized that the Notice of Allowance enhances the company's intellectual property portfolio and reflects the potential of its cell-based technology for developing therapies across various indications [3]. - The ImmCelz platform involves reprogramming a patient's immune cells outside the body with optimized cell-free factors before re-injecting them, which is believed to enhance their regenerative properties [4]. - Creative Medical is focused on pioneering regenerative medicine solutions across multiple indications, including pain management, neurology, and urology [5].

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of 3D Systems Corporation (NYSE: DDD). Shareholders who purchased shares of DDD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/3d-systems-corporation-loss-submission-form/?id=155073&from=3 CLASS PERIOD: Aug ...

NFL super-agent Leigh Steinberg opens up about the brain trauma crisis in football and his mission to protect athletes through advocacy, research, and a groundbreaking collaboration on stem cell therapy. Learn more: https://european-wellness.eu/ The man who inspired the multiple award-winning movie “Jerry Maguire” meets the pioneering stem cell scientist who is transforming regenerative medicine. Together, they may just hold the key to healing the silent epidemic of sports-related brain injuries. A ...

Core Insights - Adia Nutrition, Inc. has received full approval from the Agency for Health Care Administration (AHCA) for its clinic, Adia Med of Winter Park, allowing it to accept insurance for treatments [2][4][5] - This approval positions Adia Med as a leading provider of innovative therapies, including Autologous Hematopoietic Stem Cell Transplantation (aHSCT) for Multiple Sclerosis and other autoimmune conditions [4][6] - The clinic aims to enhance patient access to life-changing treatments by advocating for insurance coverage, thereby reducing financial barriers [5][6] Company Overview - Adia Nutrition, Inc. is a publicly traded company focused on revolutionizing healthcare through innovative regenerative medicine and nutritional supplements [7] - The company operates two main divisions: a supplement division offering premium organic supplements and a medical division specializing in advanced stem cell therapies [7] - Adia Med of Winter Park opened in January 2025 and is designed to provide personalized regenerative treatments [6][7] Market Context - The approval by AHCA allows Adia Nutrition to enter the $4.9 trillion healthcare insurance market, enhancing its growth potential [6] - By accepting insurance, the company can better serve patients and expand its reach within the healthcare sector [5][6]

Core Insights - BioRestorative Therapies, Inc. has appointed Sandy Lipkins as a leader in technology commercialization and business development, effective June 9, 2025, to enhance strategic alliances and licensing agreements [1][2][3] Company Overview - BioRestorative Therapies focuses on regenerative medicine, particularly stem cell-based therapies, with two main clinical development programs targeting disc/spine disease and metabolic disorders [5] - The company operates a commercial BioCosmeceutical platform, which includes a cell-based secretome product designed to reduce fine lines and wrinkles [7] Leadership Background - Sandy Lipkins brings over 30 years of experience in venture capital, finance, and sales, with a strong focus on anti-aging and wellness sectors, and has a proven track record in scaling companies and expanding market reach [2][3] - His expertise in stem cells and regenerative medicine is expected to drive significant value creation for BioRestorative as it advances its clinical pipeline and commercial offerings [3][4] Clinical Development Programs - The Disc/Spine Program includes BRTX-100, a cell therapy candidate for treating painful lumbosacral disc disorders, currently in Phase 2 clinical trials [5] - The Metabolic Program, ThermoStem, aims to develop therapies targeting obesity and metabolic disorders using brown adipose-derived stem cells [6] Future Aspirations - The company aims to accelerate growth and expand its BioCosmeceuticals platform under Lipkins' leadership, with a focus on bringing transformative regenerative solutions to both domestic and international markets [4][3]

CANTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Summary: Net revenue of $86.7 million for the first quarter of 2025, a decrease of $23.3 million compared to net r ...